Advertisement

Index by author

February 01, 2017; Volume 360,Issue 2

A

  1. Abbadie, C.

    1. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder
      J. Di Salvo, H. Nagabukuro, L. A. Wickham, C. Abbadie, J. A. DeMartino, A. Fitzmaurice, L. Gichuru, A. Kulick, M. J. Donnelly, N. Jochnowitz, A. L. Hurley, A. Pereira, A. Sanfiz, G. Veronin, K. Villa, J. Woods, B. Zamlynny, E. Zycband, G.M. Salituro, T. Frenkl, A. E. Weber, S. D. Edmondson and M. Struthers
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 346-355; DOI: https://doi.org/10.1124/jpet.116.237313

  2. Abeywardena, Mahinda Yapa

    1. Open Access
      Effects of Antihypertensive Agents on Intestinal Contractility in the Spontaneously Hypertensive Rat: Angiotensin Receptor System Downregulation by Losartan
      Glen Stephen Patten and Mahinda Yapa Abeywardena
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 260-266; DOI: https://doi.org/10.1124/jpet.116.237586

  3. Ahmed, Aamir

    1. Intracellular Calcium Mobilization in Response to Ion Channel Regulators via a Calcium-Induced Calcium Release Mechanism
      Open Access
      Intracellular Calcium Mobilization in Response to Ion Channel Regulators via a Calcium-Induced Calcium Release Mechanism
      Terry Petrou, Hervør L. Olsen, Christopher Thrasivoulou, John R. Masters, Jonathan F. Ashmore and Aamir Ahmed
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 378-387; DOI: https://doi.org/10.1124/jpet.116.236695

  4. Aiello, Robert J.

    1. Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension
      Robert J. Aiello, Patricia-Ann Bourassa, Qing Zhang, Jeffrey Dubins, Daniel R. Goldberg, Stéphane De Lombaert, Marc Humbert, Christophe Guignabert, Maria A. Cavasin, Timothy A. McKinsey and Vishwas Paralkar
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 267-279; DOI: https://doi.org/10.1124/jpet.116.237933

  5. Albert, Christopher

    1. Response to “Tenofovir Disoproxil Fumarate Is Not an Inhibitor of Human Organic Cation Transporter 1”
      Gerard Minuesa, Christopher Albert, Marçal Pastor-Anglada, Javier Martinez-Picado and Hermann Koepsell
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 343-345; DOI: https://doi.org/10.1124/jpet.116.239004

  6. Ashmore, Jonathan F.

    1. Intracellular Calcium Mobilization in Response to Ion Channel Regulators via a Calcium-Induced Calcium Release Mechanism
      Open Access
      Intracellular Calcium Mobilization in Response to Ion Channel Regulators via a Calcium-Induced Calcium Release Mechanism
      Terry Petrou, Hervør L. Olsen, Christopher Thrasivoulou, John R. Masters, Jonathan F. Ashmore and Aamir Ahmed
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 378-387; DOI: https://doi.org/10.1124/jpet.116.236695

B

  1. Bartol, Anna

    1. Engineered Context-Sensitive Agonism: Tissue-Selective Drug Signaling through a G Protein-Coupled Receptor
      Wiebke K. Seemann, Daniela Wenzel, Ramona Schrage, Justine Etscheid, Theresa Bödefeld, Anna Bartol, Mareille Warnken, Philipp Sasse, Jessica Klöckner, Ulrike Holzgrabe, Marco DeAmici, Eberhard Schlicker, Kurt Racké, Evi Kostenis, Rainer Meyer, Bernd K. Fleischmann and Klaus Mohr
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 289-299; DOI: https://doi.org/10.1124/jpet.116.237149

  2. Beil, Michael

    1. Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach
      Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach
      Nelleke Snelder, Bart A. Ploeger, Olivier Luttringer, Dean F. Rigel, Randy L. Webb, David Feldman, Fumin Fu, Michael Beil, Liang Jin, Donald R. Stanski and Meindert Danhof
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 356-367; DOI: https://doi.org/10.1124/jpet.116.236208

  3. Bödefeld, Theresa

    1. Engineered Context-Sensitive Agonism: Tissue-Selective Drug Signaling through a G Protein-Coupled Receptor
      Wiebke K. Seemann, Daniela Wenzel, Ramona Schrage, Justine Etscheid, Theresa Bödefeld, Anna Bartol, Mareille Warnken, Philipp Sasse, Jessica Klöckner, Ulrike Holzgrabe, Marco DeAmici, Eberhard Schlicker, Kurt Racké, Evi Kostenis, Rainer Meyer, Bernd K. Fleischmann and Klaus Mohr
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 289-299; DOI: https://doi.org/10.1124/jpet.116.237149

  4. Bourassa, Patricia-Ann

    1. Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension
      Robert J. Aiello, Patricia-Ann Bourassa, Qing Zhang, Jeffrey Dubins, Daniel R. Goldberg, Stéphane De Lombaert, Marc Humbert, Christophe Guignabert, Maria A. Cavasin, Timothy A. McKinsey and Vishwas Paralkar
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 267-279; DOI: https://doi.org/10.1124/jpet.116.237933

  5. Butt, Mark

    1. Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease
      Jeffrey Peng, Jill Dalton, Mark Butt, Kristin Tracy, Derek Kennedy, Peter Haroldsen, Rhea Cahayag, Stephen Zoog, Charles A. O’Neill and Laurie S. Tsuruda
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 313-323; DOI: https://doi.org/10.1124/jpet.116.235952

C

  1. Cahayag, Rhea

    1. Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease
      Jeffrey Peng, Jill Dalton, Mark Butt, Kristin Tracy, Derek Kennedy, Peter Haroldsen, Rhea Cahayag, Stephen Zoog, Charles A. O’Neill and Laurie S. Tsuruda
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 313-323; DOI: https://doi.org/10.1124/jpet.116.235952

  2. Cavasin, Maria A.

    1. Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension
      Robert J. Aiello, Patricia-Ann Bourassa, Qing Zhang, Jeffrey Dubins, Daniel R. Goldberg, Stéphane De Lombaert, Marc Humbert, Christophe Guignabert, Maria A. Cavasin, Timothy A. McKinsey and Vishwas Paralkar
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 267-279; DOI: https://doi.org/10.1124/jpet.116.237933

  3. Chatterjee, Mitali

    1. Allylpyrocatechol Attenuates Collagen-Induced Arthritis via Attenuation of Oxidative Stress Secondary to Modulation of the MAPK, JAK/STAT, and Nrf2/HO-1 Pathways
      Allylpyrocatechol Attenuates Collagen-Induced Arthritis via Attenuation of Oxidative Stress Secondary to Modulation of the MAPK, JAK/STAT, and Nrf2/HO-1 Pathways
      Soumita De, Alak Manna, Sunanda Kundu, Sritama De Sarkar, Uttara Chatterjee, Tuhinadri Sen, Subrata Chattopadhyay and Mitali Chatterjee
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 249-259; DOI: https://doi.org/10.1124/jpet.116.238444

  4. Chatterjee, Uttara

    1. Allylpyrocatechol Attenuates Collagen-Induced Arthritis via Attenuation of Oxidative Stress Secondary to Modulation of the MAPK, JAK/STAT, and Nrf2/HO-1 Pathways
      Allylpyrocatechol Attenuates Collagen-Induced Arthritis via Attenuation of Oxidative Stress Secondary to Modulation of the MAPK, JAK/STAT, and Nrf2/HO-1 Pathways
      Soumita De, Alak Manna, Sunanda Kundu, Sritama De Sarkar, Uttara Chatterjee, Tuhinadri Sen, Subrata Chattopadhyay and Mitali Chatterjee
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 249-259; DOI: https://doi.org/10.1124/jpet.116.238444

  5. Chattopadhyay, Subrata

    1. Allylpyrocatechol Attenuates Collagen-Induced Arthritis via Attenuation of Oxidative Stress Secondary to Modulation of the MAPK, JAK/STAT, and Nrf2/HO-1 Pathways
      Allylpyrocatechol Attenuates Collagen-Induced Arthritis via Attenuation of Oxidative Stress Secondary to Modulation of the MAPK, JAK/STAT, and Nrf2/HO-1 Pathways
      Soumita De, Alak Manna, Sunanda Kundu, Sritama De Sarkar, Uttara Chatterjee, Tuhinadri Sen, Subrata Chattopadhyay and Mitali Chatterjee
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 249-259; DOI: https://doi.org/10.1124/jpet.116.238444

D

  1. Dahal, Sujata

    1. Behavioral Characterization of κ Opioid Receptor Agonist Spiradoline and Cannabinoid Receptor Agonist CP55940 Mixtures in Rats
      Vanessa Minervini, Sujata Dahal and Charles P. France
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 280-287; DOI: https://doi.org/10.1124/jpet.116.235630

  2. Dalton, Jill

    1. Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease
      Jeffrey Peng, Jill Dalton, Mark Butt, Kristin Tracy, Derek Kennedy, Peter Haroldsen, Rhea Cahayag, Stephen Zoog, Charles A. O’Neill and Laurie S. Tsuruda
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 313-323; DOI: https://doi.org/10.1124/jpet.116.235952

  3. Danhof, Meindert

    1. Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach
      Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach
      Nelleke Snelder, Bart A. Ploeger, Olivier Luttringer, Dean F. Rigel, Randy L. Webb, David Feldman, Fumin Fu, Michael Beil, Liang Jin, Donald R. Stanski and Meindert Danhof
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 356-367; DOI: https://doi.org/10.1124/jpet.116.236208

  4. De, Soumita

    1. Allylpyrocatechol Attenuates Collagen-Induced Arthritis via Attenuation of Oxidative Stress Secondary to Modulation of the MAPK, JAK/STAT, and Nrf2/HO-1 Pathways
      Allylpyrocatechol Attenuates Collagen-Induced Arthritis via Attenuation of Oxidative Stress Secondary to Modulation of the MAPK, JAK/STAT, and Nrf2/HO-1 Pathways
      Soumita De, Alak Manna, Sunanda Kundu, Sritama De Sarkar, Uttara Chatterjee, Tuhinadri Sen, Subrata Chattopadhyay and Mitali Chatterjee
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 249-259; DOI: https://doi.org/10.1124/jpet.116.238444

  5. DeAmici, Marco

    1. Engineered Context-Sensitive Agonism: Tissue-Selective Drug Signaling through a G Protein-Coupled Receptor
      Wiebke K. Seemann, Daniela Wenzel, Ramona Schrage, Justine Etscheid, Theresa Bödefeld, Anna Bartol, Mareille Warnken, Philipp Sasse, Jessica Klöckner, Ulrike Holzgrabe, Marco DeAmici, Eberhard Schlicker, Kurt Racké, Evi Kostenis, Rainer Meyer, Bernd K. Fleischmann and Klaus Mohr
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 289-299; DOI: https://doi.org/10.1124/jpet.116.237149

  6. De Lombaert, Stéphane

    1. Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension
      Robert J. Aiello, Patricia-Ann Bourassa, Qing Zhang, Jeffrey Dubins, Daniel R. Goldberg, Stéphane De Lombaert, Marc Humbert, Christophe Guignabert, Maria A. Cavasin, Timothy A. McKinsey and Vishwas Paralkar
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 267-279; DOI: https://doi.org/10.1124/jpet.116.237933

  7. DeMartino, J. A.

    1. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder
      J. Di Salvo, H. Nagabukuro, L. A. Wickham, C. Abbadie, J. A. DeMartino, A. Fitzmaurice, L. Gichuru, A. Kulick, M. J. Donnelly, N. Jochnowitz, A. L. Hurley, A. Pereira, A. Sanfiz, G. Veronin, K. Villa, J. Woods, B. Zamlynny, E. Zycband, G.M. Salituro, T. Frenkl, A. E. Weber, S. D. Edmondson and M. Struthers
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 346-355; DOI: https://doi.org/10.1124/jpet.116.237313

  8. De Sarkar, Sritama

    1. Allylpyrocatechol Attenuates Collagen-Induced Arthritis via Attenuation of Oxidative Stress Secondary to Modulation of the MAPK, JAK/STAT, and Nrf2/HO-1 Pathways
      Allylpyrocatechol Attenuates Collagen-Induced Arthritis via Attenuation of Oxidative Stress Secondary to Modulation of the MAPK, JAK/STAT, and Nrf2/HO-1 Pathways
      Soumita De, Alak Manna, Sunanda Kundu, Sritama De Sarkar, Uttara Chatterjee, Tuhinadri Sen, Subrata Chattopadhyay and Mitali Chatterjee
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 249-259; DOI: https://doi.org/10.1124/jpet.116.238444

  9. Dhopeshwarkar, Amey

    1. Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists
      Amey Dhopeshwarkar, Natalia Murataeva, Alex Makriyannis, Alex Straiker and Ken Mackie
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 300-311; DOI: https://doi.org/10.1124/jpet.116.236539

  10. Di Salvo, J.

    1. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder
      J. Di Salvo, H. Nagabukuro, L. A. Wickham, C. Abbadie, J. A. DeMartino, A. Fitzmaurice, L. Gichuru, A. Kulick, M. J. Donnelly, N. Jochnowitz, A. L. Hurley, A. Pereira, A. Sanfiz, G. Veronin, K. Villa, J. Woods, B. Zamlynny, E. Zycband, G.M. Salituro, T. Frenkl, A. E. Weber, S. D. Edmondson and M. Struthers
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 346-355; DOI: https://doi.org/10.1124/jpet.116.237313

  11. Donnelly, M. J.

    1. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder
      J. Di Salvo, H. Nagabukuro, L. A. Wickham, C. Abbadie, J. A. DeMartino, A. Fitzmaurice, L. Gichuru, A. Kulick, M. J. Donnelly, N. Jochnowitz, A. L. Hurley, A. Pereira, A. Sanfiz, G. Veronin, K. Villa, J. Woods, B. Zamlynny, E. Zycband, G.M. Salituro, T. Frenkl, A. E. Weber, S. D. Edmondson and M. Struthers
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 346-355; DOI: https://doi.org/10.1124/jpet.116.237313

  12. Dubins, Jeffrey

    1. Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension
      Robert J. Aiello, Patricia-Ann Bourassa, Qing Zhang, Jeffrey Dubins, Daniel R. Goldberg, Stéphane De Lombaert, Marc Humbert, Christophe Guignabert, Maria A. Cavasin, Timothy A. McKinsey and Vishwas Paralkar
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 267-279; DOI: https://doi.org/10.1124/jpet.116.237933

E

  1. Edmondson, S. D.

    1. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder
      J. Di Salvo, H. Nagabukuro, L. A. Wickham, C. Abbadie, J. A. DeMartino, A. Fitzmaurice, L. Gichuru, A. Kulick, M. J. Donnelly, N. Jochnowitz, A. L. Hurley, A. Pereira, A. Sanfiz, G. Veronin, K. Villa, J. Woods, B. Zamlynny, E. Zycband, G.M. Salituro, T. Frenkl, A. E. Weber, S. D. Edmondson and M. Struthers
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 346-355; DOI: https://doi.org/10.1124/jpet.116.237313

  2. Etscheid, Justine

    1. Engineered Context-Sensitive Agonism: Tissue-Selective Drug Signaling through a G Protein-Coupled Receptor
      Wiebke K. Seemann, Daniela Wenzel, Ramona Schrage, Justine Etscheid, Theresa Bödefeld, Anna Bartol, Mareille Warnken, Philipp Sasse, Jessica Klöckner, Ulrike Holzgrabe, Marco DeAmici, Eberhard Schlicker, Kurt Racké, Evi Kostenis, Rainer Meyer, Bernd K. Fleischmann and Klaus Mohr
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 289-299; DOI: https://doi.org/10.1124/jpet.116.237149

F

  1. Feldman, David

    1. Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach
      Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach
      Nelleke Snelder, Bart A. Ploeger, Olivier Luttringer, Dean F. Rigel, Randy L. Webb, David Feldman, Fumin Fu, Michael Beil, Liang Jin, Donald R. Stanski and Meindert Danhof
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 356-367; DOI: https://doi.org/10.1124/jpet.116.236208

  2. Fitzmaurice, A.

    1. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder
      J. Di Salvo, H. Nagabukuro, L. A. Wickham, C. Abbadie, J. A. DeMartino, A. Fitzmaurice, L. Gichuru, A. Kulick, M. J. Donnelly, N. Jochnowitz, A. L. Hurley, A. Pereira, A. Sanfiz, G. Veronin, K. Villa, J. Woods, B. Zamlynny, E. Zycband, G.M. Salituro, T. Frenkl, A. E. Weber, S. D. Edmondson and M. Struthers
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 346-355; DOI: https://doi.org/10.1124/jpet.116.237313

  3. Fleischmann, Bernd K.

    1. Engineered Context-Sensitive Agonism: Tissue-Selective Drug Signaling through a G Protein-Coupled Receptor
      Wiebke K. Seemann, Daniela Wenzel, Ramona Schrage, Justine Etscheid, Theresa Bödefeld, Anna Bartol, Mareille Warnken, Philipp Sasse, Jessica Klöckner, Ulrike Holzgrabe, Marco DeAmici, Eberhard Schlicker, Kurt Racké, Evi Kostenis, Rainer Meyer, Bernd K. Fleischmann and Klaus Mohr
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 289-299; DOI: https://doi.org/10.1124/jpet.116.237149

  4. France, Charles P.

    1. Behavioral Characterization of κ Opioid Receptor Agonist Spiradoline and Cannabinoid Receptor Agonist CP55940 Mixtures in Rats
      Vanessa Minervini, Sujata Dahal and Charles P. France
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 280-287; DOI: https://doi.org/10.1124/jpet.116.235630

  5. Frenkl, T.

    1. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder
      J. Di Salvo, H. Nagabukuro, L. A. Wickham, C. Abbadie, J. A. DeMartino, A. Fitzmaurice, L. Gichuru, A. Kulick, M. J. Donnelly, N. Jochnowitz, A. L. Hurley, A. Pereira, A. Sanfiz, G. Veronin, K. Villa, J. Woods, B. Zamlynny, E. Zycband, G.M. Salituro, T. Frenkl, A. E. Weber, S. D. Edmondson and M. Struthers
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 346-355; DOI: https://doi.org/10.1124/jpet.116.237313

  6. Fu, Fumin

    1. Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach
      Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach
      Nelleke Snelder, Bart A. Ploeger, Olivier Luttringer, Dean F. Rigel, Randy L. Webb, David Feldman, Fumin Fu, Michael Beil, Liang Jin, Donald R. Stanski and Meindert Danhof
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 356-367; DOI: https://doi.org/10.1124/jpet.116.236208

G

  1. Ganey, Patricia E.

    1. Idiosyncratic Drug-Induced Liver Injury: Is Drug-Cytokine Interaction the Linchpin?
      Robert A. Roth, Ashley R. Maiuri and Patricia E. Ganey
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 368-377; DOI: https://doi.org/10.1124/jpet.116.237578

  2. Gichuru, L.

    1. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder
      J. Di Salvo, H. Nagabukuro, L. A. Wickham, C. Abbadie, J. A. DeMartino, A. Fitzmaurice, L. Gichuru, A. Kulick, M. J. Donnelly, N. Jochnowitz, A. L. Hurley, A. Pereira, A. Sanfiz, G. Veronin, K. Villa, J. Woods, B. Zamlynny, E. Zycband, G.M. Salituro, T. Frenkl, A. E. Weber, S. D. Edmondson and M. Struthers
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 346-355; DOI: https://doi.org/10.1124/jpet.116.237313

  3. Giembycz, Mark A.

    1. GS-5759, a Bifunctional β2-Adrenoceptor Agonist and Phosphodiesterase 4 Inhibitor for Chronic Obstructive Pulmonary Disease with a Unique Mode of Action: Effects on Gene Expression in Human Airway Epithelial Cells
      Taruna Joshi, Dong Yan, Omar Hamed, Stacey L. Tannheimer, Gary B. Phillips, Clifford D. Wright, Musong Kim, Michael Salmon, Robert Newton and Mark A. Giembycz
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 324-340; DOI: https://doi.org/10.1124/jpet.116.237743

  4. Goldberg, Daniel R.

    1. Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension
      Robert J. Aiello, Patricia-Ann Bourassa, Qing Zhang, Jeffrey Dubins, Daniel R. Goldberg, Stéphane De Lombaert, Marc Humbert, Christophe Guignabert, Maria A. Cavasin, Timothy A. McKinsey and Vishwas Paralkar
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 267-279; DOI: https://doi.org/10.1124/jpet.116.237933

  5. Guignabert, Christophe

    1. Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension
      Robert J. Aiello, Patricia-Ann Bourassa, Qing Zhang, Jeffrey Dubins, Daniel R. Goldberg, Stéphane De Lombaert, Marc Humbert, Christophe Guignabert, Maria A. Cavasin, Timothy A. McKinsey and Vishwas Paralkar
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 267-279; DOI: https://doi.org/10.1124/jpet.116.237933

H

  1. Hamed, Omar

    1. GS-5759, a Bifunctional β2-Adrenoceptor Agonist and Phosphodiesterase 4 Inhibitor for Chronic Obstructive Pulmonary Disease with a Unique Mode of Action: Effects on Gene Expression in Human Airway Epithelial Cells
      Taruna Joshi, Dong Yan, Omar Hamed, Stacey L. Tannheimer, Gary B. Phillips, Clifford D. Wright, Musong Kim, Michael Salmon, Robert Newton and Mark A. Giembycz
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 324-340; DOI: https://doi.org/10.1124/jpet.116.237743

  2. Haroldsen, Peter

    1. Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease
      Jeffrey Peng, Jill Dalton, Mark Butt, Kristin Tracy, Derek Kennedy, Peter Haroldsen, Rhea Cahayag, Stephen Zoog, Charles A. O’Neill and Laurie S. Tsuruda
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 313-323; DOI: https://doi.org/10.1124/jpet.116.235952

  3. Holzgrabe, Ulrike

    1. Engineered Context-Sensitive Agonism: Tissue-Selective Drug Signaling through a G Protein-Coupled Receptor
      Wiebke K. Seemann, Daniela Wenzel, Ramona Schrage, Justine Etscheid, Theresa Bödefeld, Anna Bartol, Mareille Warnken, Philipp Sasse, Jessica Klöckner, Ulrike Holzgrabe, Marco DeAmici, Eberhard Schlicker, Kurt Racké, Evi Kostenis, Rainer Meyer, Bernd K. Fleischmann and Klaus Mohr
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 289-299; DOI: https://doi.org/10.1124/jpet.116.237149

  4. Humbert, Marc

    1. Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension
      Robert J. Aiello, Patricia-Ann Bourassa, Qing Zhang, Jeffrey Dubins, Daniel R. Goldberg, Stéphane De Lombaert, Marc Humbert, Christophe Guignabert, Maria A. Cavasin, Timothy A. McKinsey and Vishwas Paralkar
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 267-279; DOI: https://doi.org/10.1124/jpet.116.237933

  5. Humphreys, W. Griffith

    1. Tenofovir Disoproxil Fumarate Is Not an Inhibitor of Human Organic Cation Transporter 1
      Hong Shen, Wenying Li, W. Griffith Humphreys and Yurong Lai
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 341-342; DOI: https://doi.org/10.1124/jpet.116.238337

  6. Hurley, A. L.

    1. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder
      J. Di Salvo, H. Nagabukuro, L. A. Wickham, C. Abbadie, J. A. DeMartino, A. Fitzmaurice, L. Gichuru, A. Kulick, M. J. Donnelly, N. Jochnowitz, A. L. Hurley, A. Pereira, A. Sanfiz, G. Veronin, K. Villa, J. Woods, B. Zamlynny, E. Zycband, G.M. Salituro, T. Frenkl, A. E. Weber, S. D. Edmondson and M. Struthers
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 346-355; DOI: https://doi.org/10.1124/jpet.116.237313

J

  1. Jin, Liang

    1. Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach
      Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach
      Nelleke Snelder, Bart A. Ploeger, Olivier Luttringer, Dean F. Rigel, Randy L. Webb, David Feldman, Fumin Fu, Michael Beil, Liang Jin, Donald R. Stanski and Meindert Danhof
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 356-367; DOI: https://doi.org/10.1124/jpet.116.236208

  2. Jochnowitz, N.

    1. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder
      J. Di Salvo, H. Nagabukuro, L. A. Wickham, C. Abbadie, J. A. DeMartino, A. Fitzmaurice, L. Gichuru, A. Kulick, M. J. Donnelly, N. Jochnowitz, A. L. Hurley, A. Pereira, A. Sanfiz, G. Veronin, K. Villa, J. Woods, B. Zamlynny, E. Zycband, G.M. Salituro, T. Frenkl, A. E. Weber, S. D. Edmondson and M. Struthers
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 346-355; DOI: https://doi.org/10.1124/jpet.116.237313

  3. Joshi, Taruna

    1. GS-5759, a Bifunctional β2-Adrenoceptor Agonist and Phosphodiesterase 4 Inhibitor for Chronic Obstructive Pulmonary Disease with a Unique Mode of Action: Effects on Gene Expression in Human Airway Epithelial Cells
      Taruna Joshi, Dong Yan, Omar Hamed, Stacey L. Tannheimer, Gary B. Phillips, Clifford D. Wright, Musong Kim, Michael Salmon, Robert Newton and Mark A. Giembycz
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 324-340; DOI: https://doi.org/10.1124/jpet.116.237743

K

  1. Kennedy, Derek

    1. Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease
      Jeffrey Peng, Jill Dalton, Mark Butt, Kristin Tracy, Derek Kennedy, Peter Haroldsen, Rhea Cahayag, Stephen Zoog, Charles A. O’Neill and Laurie S. Tsuruda
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 313-323; DOI: https://doi.org/10.1124/jpet.116.235952

  2. Kim, Musong

    1. GS-5759, a Bifunctional β2-Adrenoceptor Agonist and Phosphodiesterase 4 Inhibitor for Chronic Obstructive Pulmonary Disease with a Unique Mode of Action: Effects on Gene Expression in Human Airway Epithelial Cells
      Taruna Joshi, Dong Yan, Omar Hamed, Stacey L. Tannheimer, Gary B. Phillips, Clifford D. Wright, Musong Kim, Michael Salmon, Robert Newton and Mark A. Giembycz
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 324-340; DOI: https://doi.org/10.1124/jpet.116.237743

  3. Klöckner, Jessica

    1. Engineered Context-Sensitive Agonism: Tissue-Selective Drug Signaling through a G Protein-Coupled Receptor
      Wiebke K. Seemann, Daniela Wenzel, Ramona Schrage, Justine Etscheid, Theresa Bödefeld, Anna Bartol, Mareille Warnken, Philipp Sasse, Jessica Klöckner, Ulrike Holzgrabe, Marco DeAmici, Eberhard Schlicker, Kurt Racké, Evi Kostenis, Rainer Meyer, Bernd K. Fleischmann and Klaus Mohr
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 289-299; DOI: https://doi.org/10.1124/jpet.116.237149

  4. Koepsell, Hermann

    1. Response to “Tenofovir Disoproxil Fumarate Is Not an Inhibitor of Human Organic Cation Transporter 1”
      Gerard Minuesa, Christopher Albert, Marçal Pastor-Anglada, Javier Martinez-Picado and Hermann Koepsell
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 343-345; DOI: https://doi.org/10.1124/jpet.116.239004

  5. Kostenis, Evi

    1. Engineered Context-Sensitive Agonism: Tissue-Selective Drug Signaling through a G Protein-Coupled Receptor
      Wiebke K. Seemann, Daniela Wenzel, Ramona Schrage, Justine Etscheid, Theresa Bödefeld, Anna Bartol, Mareille Warnken, Philipp Sasse, Jessica Klöckner, Ulrike Holzgrabe, Marco DeAmici, Eberhard Schlicker, Kurt Racké, Evi Kostenis, Rainer Meyer, Bernd K. Fleischmann and Klaus Mohr
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 289-299; DOI: https://doi.org/10.1124/jpet.116.237149

  6. Kulick, A.

    1. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder
      J. Di Salvo, H. Nagabukuro, L. A. Wickham, C. Abbadie, J. A. DeMartino, A. Fitzmaurice, L. Gichuru, A. Kulick, M. J. Donnelly, N. Jochnowitz, A. L. Hurley, A. Pereira, A. Sanfiz, G. Veronin, K. Villa, J. Woods, B. Zamlynny, E. Zycband, G.M. Salituro, T. Frenkl, A. E. Weber, S. D. Edmondson and M. Struthers
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 346-355; DOI: https://doi.org/10.1124/jpet.116.237313

  7. Kundu, Sunanda

    1. Allylpyrocatechol Attenuates Collagen-Induced Arthritis via Attenuation of Oxidative Stress Secondary to Modulation of the MAPK, JAK/STAT, and Nrf2/HO-1 Pathways
      Allylpyrocatechol Attenuates Collagen-Induced Arthritis via Attenuation of Oxidative Stress Secondary to Modulation of the MAPK, JAK/STAT, and Nrf2/HO-1 Pathways
      Soumita De, Alak Manna, Sunanda Kundu, Sritama De Sarkar, Uttara Chatterjee, Tuhinadri Sen, Subrata Chattopadhyay and Mitali Chatterjee
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 249-259; DOI: https://doi.org/10.1124/jpet.116.238444

L

  1. Lai, Yurong

    1. Tenofovir Disoproxil Fumarate Is Not an Inhibitor of Human Organic Cation Transporter 1
      Hong Shen, Wenying Li, W. Griffith Humphreys and Yurong Lai
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 341-342; DOI: https://doi.org/10.1124/jpet.116.238337

  2. Li, Wenying

    1. Tenofovir Disoproxil Fumarate Is Not an Inhibitor of Human Organic Cation Transporter 1
      Hong Shen, Wenying Li, W. Griffith Humphreys and Yurong Lai
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 341-342; DOI: https://doi.org/10.1124/jpet.116.238337

  3. Luttringer, Olivier

    1. Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach
      Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach
      Nelleke Snelder, Bart A. Ploeger, Olivier Luttringer, Dean F. Rigel, Randy L. Webb, David Feldman, Fumin Fu, Michael Beil, Liang Jin, Donald R. Stanski and Meindert Danhof
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 356-367; DOI: https://doi.org/10.1124/jpet.116.236208

M

  1. Mackie, Ken

    1. Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists
      Amey Dhopeshwarkar, Natalia Murataeva, Alex Makriyannis, Alex Straiker and Ken Mackie
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 300-311; DOI: https://doi.org/10.1124/jpet.116.236539

  2. Maiuri, Ashley R.

    1. Idiosyncratic Drug-Induced Liver Injury: Is Drug-Cytokine Interaction the Linchpin?
      Robert A. Roth, Ashley R. Maiuri and Patricia E. Ganey
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 368-377; DOI: https://doi.org/10.1124/jpet.116.237578

  3. Makriyannis, Alex

    1. Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists
      Amey Dhopeshwarkar, Natalia Murataeva, Alex Makriyannis, Alex Straiker and Ken Mackie
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 300-311; DOI: https://doi.org/10.1124/jpet.116.236539

  4. Manna, Alak

    1. Allylpyrocatechol Attenuates Collagen-Induced Arthritis via Attenuation of Oxidative Stress Secondary to Modulation of the MAPK, JAK/STAT, and Nrf2/HO-1 Pathways
      Allylpyrocatechol Attenuates Collagen-Induced Arthritis via Attenuation of Oxidative Stress Secondary to Modulation of the MAPK, JAK/STAT, and Nrf2/HO-1 Pathways
      Soumita De, Alak Manna, Sunanda Kundu, Sritama De Sarkar, Uttara Chatterjee, Tuhinadri Sen, Subrata Chattopadhyay and Mitali Chatterjee
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 249-259; DOI: https://doi.org/10.1124/jpet.116.238444

  5. Martinez-Picado, Javier

    1. Response to “Tenofovir Disoproxil Fumarate Is Not an Inhibitor of Human Organic Cation Transporter 1”
      Gerard Minuesa, Christopher Albert, Marçal Pastor-Anglada, Javier Martinez-Picado and Hermann Koepsell
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 343-345; DOI: https://doi.org/10.1124/jpet.116.239004

  6. Masters, John R.

    1. Intracellular Calcium Mobilization in Response to Ion Channel Regulators via a Calcium-Induced Calcium Release Mechanism
      Open Access
      Intracellular Calcium Mobilization in Response to Ion Channel Regulators via a Calcium-Induced Calcium Release Mechanism
      Terry Petrou, Hervør L. Olsen, Christopher Thrasivoulou, John R. Masters, Jonathan F. Ashmore and Aamir Ahmed
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 378-387; DOI: https://doi.org/10.1124/jpet.116.236695

  7. McKinsey, Timothy A.

    1. Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension
      Robert J. Aiello, Patricia-Ann Bourassa, Qing Zhang, Jeffrey Dubins, Daniel R. Goldberg, Stéphane De Lombaert, Marc Humbert, Christophe Guignabert, Maria A. Cavasin, Timothy A. McKinsey and Vishwas Paralkar
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 267-279; DOI: https://doi.org/10.1124/jpet.116.237933

  8. Meyer, Rainer

    1. Engineered Context-Sensitive Agonism: Tissue-Selective Drug Signaling through a G Protein-Coupled Receptor
      Wiebke K. Seemann, Daniela Wenzel, Ramona Schrage, Justine Etscheid, Theresa Bödefeld, Anna Bartol, Mareille Warnken, Philipp Sasse, Jessica Klöckner, Ulrike Holzgrabe, Marco DeAmici, Eberhard Schlicker, Kurt Racké, Evi Kostenis, Rainer Meyer, Bernd K. Fleischmann and Klaus Mohr
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 289-299; DOI: https://doi.org/10.1124/jpet.116.237149

  9. Minervini, Vanessa

    1. Behavioral Characterization of κ Opioid Receptor Agonist Spiradoline and Cannabinoid Receptor Agonist CP55940 Mixtures in Rats
      Vanessa Minervini, Sujata Dahal and Charles P. France
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 280-287; DOI: https://doi.org/10.1124/jpet.116.235630

  10. Minuesa, Gerard

    1. Response to “Tenofovir Disoproxil Fumarate Is Not an Inhibitor of Human Organic Cation Transporter 1”
      Gerard Minuesa, Christopher Albert, Marçal Pastor-Anglada, Javier Martinez-Picado and Hermann Koepsell
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 343-345; DOI: https://doi.org/10.1124/jpet.116.239004

  11. Mohr, Klaus

    1. Engineered Context-Sensitive Agonism: Tissue-Selective Drug Signaling through a G Protein-Coupled Receptor
      Wiebke K. Seemann, Daniela Wenzel, Ramona Schrage, Justine Etscheid, Theresa Bödefeld, Anna Bartol, Mareille Warnken, Philipp Sasse, Jessica Klöckner, Ulrike Holzgrabe, Marco DeAmici, Eberhard Schlicker, Kurt Racké, Evi Kostenis, Rainer Meyer, Bernd K. Fleischmann and Klaus Mohr
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 289-299; DOI: https://doi.org/10.1124/jpet.116.237149

  12. Murataeva, Natalia

    1. Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists
      Amey Dhopeshwarkar, Natalia Murataeva, Alex Makriyannis, Alex Straiker and Ken Mackie
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 300-311; DOI: https://doi.org/10.1124/jpet.116.236539

N

  1. Nagabukuro, H.

    1. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder
      J. Di Salvo, H. Nagabukuro, L. A. Wickham, C. Abbadie, J. A. DeMartino, A. Fitzmaurice, L. Gichuru, A. Kulick, M. J. Donnelly, N. Jochnowitz, A. L. Hurley, A. Pereira, A. Sanfiz, G. Veronin, K. Villa, J. Woods, B. Zamlynny, E. Zycband, G.M. Salituro, T. Frenkl, A. E. Weber, S. D. Edmondson and M. Struthers
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 346-355; DOI: https://doi.org/10.1124/jpet.116.237313

  2. Newton, Robert

    1. GS-5759, a Bifunctional β2-Adrenoceptor Agonist and Phosphodiesterase 4 Inhibitor for Chronic Obstructive Pulmonary Disease with a Unique Mode of Action: Effects on Gene Expression in Human Airway Epithelial Cells
      Taruna Joshi, Dong Yan, Omar Hamed, Stacey L. Tannheimer, Gary B. Phillips, Clifford D. Wright, Musong Kim, Michael Salmon, Robert Newton and Mark A. Giembycz
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 324-340; DOI: https://doi.org/10.1124/jpet.116.237743

O

  1. O’Neill, Charles A.

    1. Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease
      Jeffrey Peng, Jill Dalton, Mark Butt, Kristin Tracy, Derek Kennedy, Peter Haroldsen, Rhea Cahayag, Stephen Zoog, Charles A. O’Neill and Laurie S. Tsuruda
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 313-323; DOI: https://doi.org/10.1124/jpet.116.235952

  2. Olsen, Hervør L.

    1. Intracellular Calcium Mobilization in Response to Ion Channel Regulators via a Calcium-Induced Calcium Release Mechanism
      Open Access
      Intracellular Calcium Mobilization in Response to Ion Channel Regulators via a Calcium-Induced Calcium Release Mechanism
      Terry Petrou, Hervør L. Olsen, Christopher Thrasivoulou, John R. Masters, Jonathan F. Ashmore and Aamir Ahmed
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 378-387; DOI: https://doi.org/10.1124/jpet.116.236695

P

  1. Paralkar, Vishwas

    1. Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension
      Robert J. Aiello, Patricia-Ann Bourassa, Qing Zhang, Jeffrey Dubins, Daniel R. Goldberg, Stéphane De Lombaert, Marc Humbert, Christophe Guignabert, Maria A. Cavasin, Timothy A. McKinsey and Vishwas Paralkar
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 267-279; DOI: https://doi.org/10.1124/jpet.116.237933

  2. Pastor-Anglada, Marçal

    1. Response to “Tenofovir Disoproxil Fumarate Is Not an Inhibitor of Human Organic Cation Transporter 1”
      Gerard Minuesa, Christopher Albert, Marçal Pastor-Anglada, Javier Martinez-Picado and Hermann Koepsell
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 343-345; DOI: https://doi.org/10.1124/jpet.116.239004

  3. Patten, Glen Stephen

    1. Open Access
      Effects of Antihypertensive Agents on Intestinal Contractility in the Spontaneously Hypertensive Rat: Angiotensin Receptor System Downregulation by Losartan
      Glen Stephen Patten and Mahinda Yapa Abeywardena
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 260-266; DOI: https://doi.org/10.1124/jpet.116.237586

  4. Peng, Jeffrey

    1. Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease
      Jeffrey Peng, Jill Dalton, Mark Butt, Kristin Tracy, Derek Kennedy, Peter Haroldsen, Rhea Cahayag, Stephen Zoog, Charles A. O’Neill and Laurie S. Tsuruda
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 313-323; DOI: https://doi.org/10.1124/jpet.116.235952

  5. Pereira, A.

    1. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder
      J. Di Salvo, H. Nagabukuro, L. A. Wickham, C. Abbadie, J. A. DeMartino, A. Fitzmaurice, L. Gichuru, A. Kulick, M. J. Donnelly, N. Jochnowitz, A. L. Hurley, A. Pereira, A. Sanfiz, G. Veronin, K. Villa, J. Woods, B. Zamlynny, E. Zycband, G.M. Salituro, T. Frenkl, A. E. Weber, S. D. Edmondson and M. Struthers
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 346-355; DOI: https://doi.org/10.1124/jpet.116.237313

  6. Petrou, Terry

    1. Intracellular Calcium Mobilization in Response to Ion Channel Regulators via a Calcium-Induced Calcium Release Mechanism
      Open Access
      Intracellular Calcium Mobilization in Response to Ion Channel Regulators via a Calcium-Induced Calcium Release Mechanism
      Terry Petrou, Hervør L. Olsen, Christopher Thrasivoulou, John R. Masters, Jonathan F. Ashmore and Aamir Ahmed
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 378-387; DOI: https://doi.org/10.1124/jpet.116.236695

  7. Phillips, Gary B.

    1. GS-5759, a Bifunctional β2-Adrenoceptor Agonist and Phosphodiesterase 4 Inhibitor for Chronic Obstructive Pulmonary Disease with a Unique Mode of Action: Effects on Gene Expression in Human Airway Epithelial Cells
      Taruna Joshi, Dong Yan, Omar Hamed, Stacey L. Tannheimer, Gary B. Phillips, Clifford D. Wright, Musong Kim, Michael Salmon, Robert Newton and Mark A. Giembycz
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 324-340; DOI: https://doi.org/10.1124/jpet.116.237743

  8. Ploeger, Bart A.

    1. Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach
      Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach
      Nelleke Snelder, Bart A. Ploeger, Olivier Luttringer, Dean F. Rigel, Randy L. Webb, David Feldman, Fumin Fu, Michael Beil, Liang Jin, Donald R. Stanski and Meindert Danhof
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 356-367; DOI: https://doi.org/10.1124/jpet.116.236208

R

  1. Racké, Kurt

    1. Engineered Context-Sensitive Agonism: Tissue-Selective Drug Signaling through a G Protein-Coupled Receptor
      Wiebke K. Seemann, Daniela Wenzel, Ramona Schrage, Justine Etscheid, Theresa Bödefeld, Anna Bartol, Mareille Warnken, Philipp Sasse, Jessica Klöckner, Ulrike Holzgrabe, Marco DeAmici, Eberhard Schlicker, Kurt Racké, Evi Kostenis, Rainer Meyer, Bernd K. Fleischmann and Klaus Mohr
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 289-299; DOI: https://doi.org/10.1124/jpet.116.237149

  2. Rigel, Dean F.

    1. Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach
      Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach
      Nelleke Snelder, Bart A. Ploeger, Olivier Luttringer, Dean F. Rigel, Randy L. Webb, David Feldman, Fumin Fu, Michael Beil, Liang Jin, Donald R. Stanski and Meindert Danhof
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 356-367; DOI: https://doi.org/10.1124/jpet.116.236208

  3. Roth, Robert A.

    1. Idiosyncratic Drug-Induced Liver Injury: Is Drug-Cytokine Interaction the Linchpin?
      Robert A. Roth, Ashley R. Maiuri and Patricia E. Ganey
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 368-377; DOI: https://doi.org/10.1124/jpet.116.237578

S

  1. Salituro, G.M.

    1. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder
      J. Di Salvo, H. Nagabukuro, L. A. Wickham, C. Abbadie, J. A. DeMartino, A. Fitzmaurice, L. Gichuru, A. Kulick, M. J. Donnelly, N. Jochnowitz, A. L. Hurley, A. Pereira, A. Sanfiz, G. Veronin, K. Villa, J. Woods, B. Zamlynny, E. Zycband, G.M. Salituro, T. Frenkl, A. E. Weber, S. D. Edmondson and M. Struthers
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 346-355; DOI: https://doi.org/10.1124/jpet.116.237313

  2. Salmon, Michael

    1. GS-5759, a Bifunctional β2-Adrenoceptor Agonist and Phosphodiesterase 4 Inhibitor for Chronic Obstructive Pulmonary Disease with a Unique Mode of Action: Effects on Gene Expression in Human Airway Epithelial Cells
      Taruna Joshi, Dong Yan, Omar Hamed, Stacey L. Tannheimer, Gary B. Phillips, Clifford D. Wright, Musong Kim, Michael Salmon, Robert Newton and Mark A. Giembycz
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 324-340; DOI: https://doi.org/10.1124/jpet.116.237743

  3. Sanfiz, A.

    1. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder
      J. Di Salvo, H. Nagabukuro, L. A. Wickham, C. Abbadie, J. A. DeMartino, A. Fitzmaurice, L. Gichuru, A. Kulick, M. J. Donnelly, N. Jochnowitz, A. L. Hurley, A. Pereira, A. Sanfiz, G. Veronin, K. Villa, J. Woods, B. Zamlynny, E. Zycband, G.M. Salituro, T. Frenkl, A. E. Weber, S. D. Edmondson and M. Struthers
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 346-355; DOI: https://doi.org/10.1124/jpet.116.237313

  4. Sasse, Philipp

    1. Engineered Context-Sensitive Agonism: Tissue-Selective Drug Signaling through a G Protein-Coupled Receptor
      Wiebke K. Seemann, Daniela Wenzel, Ramona Schrage, Justine Etscheid, Theresa Bödefeld, Anna Bartol, Mareille Warnken, Philipp Sasse, Jessica Klöckner, Ulrike Holzgrabe, Marco DeAmici, Eberhard Schlicker, Kurt Racké, Evi Kostenis, Rainer Meyer, Bernd K. Fleischmann and Klaus Mohr
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 289-299; DOI: https://doi.org/10.1124/jpet.116.237149

  5. Schlicker, Eberhard

    1. Engineered Context-Sensitive Agonism: Tissue-Selective Drug Signaling through a G Protein-Coupled Receptor
      Wiebke K. Seemann, Daniela Wenzel, Ramona Schrage, Justine Etscheid, Theresa Bödefeld, Anna Bartol, Mareille Warnken, Philipp Sasse, Jessica Klöckner, Ulrike Holzgrabe, Marco DeAmici, Eberhard Schlicker, Kurt Racké, Evi Kostenis, Rainer Meyer, Bernd K. Fleischmann and Klaus Mohr
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 289-299; DOI: https://doi.org/10.1124/jpet.116.237149

  6. Schrage, Ramona

    1. Engineered Context-Sensitive Agonism: Tissue-Selective Drug Signaling through a G Protein-Coupled Receptor
      Wiebke K. Seemann, Daniela Wenzel, Ramona Schrage, Justine Etscheid, Theresa Bödefeld, Anna Bartol, Mareille Warnken, Philipp Sasse, Jessica Klöckner, Ulrike Holzgrabe, Marco DeAmici, Eberhard Schlicker, Kurt Racké, Evi Kostenis, Rainer Meyer, Bernd K. Fleischmann and Klaus Mohr
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 289-299; DOI: https://doi.org/10.1124/jpet.116.237149

  7. Seemann, Wiebke K.

    1. Engineered Context-Sensitive Agonism: Tissue-Selective Drug Signaling through a G Protein-Coupled Receptor
      Wiebke K. Seemann, Daniela Wenzel, Ramona Schrage, Justine Etscheid, Theresa Bödefeld, Anna Bartol, Mareille Warnken, Philipp Sasse, Jessica Klöckner, Ulrike Holzgrabe, Marco DeAmici, Eberhard Schlicker, Kurt Racké, Evi Kostenis, Rainer Meyer, Bernd K. Fleischmann and Klaus Mohr
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 289-299; DOI: https://doi.org/10.1124/jpet.116.237149

  8. Sen, Tuhinadri

    1. Allylpyrocatechol Attenuates Collagen-Induced Arthritis via Attenuation of Oxidative Stress Secondary to Modulation of the MAPK, JAK/STAT, and Nrf2/HO-1 Pathways
      Allylpyrocatechol Attenuates Collagen-Induced Arthritis via Attenuation of Oxidative Stress Secondary to Modulation of the MAPK, JAK/STAT, and Nrf2/HO-1 Pathways
      Soumita De, Alak Manna, Sunanda Kundu, Sritama De Sarkar, Uttara Chatterjee, Tuhinadri Sen, Subrata Chattopadhyay and Mitali Chatterjee
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 249-259; DOI: https://doi.org/10.1124/jpet.116.238444

  9. Shen, Hong

    1. Tenofovir Disoproxil Fumarate Is Not an Inhibitor of Human Organic Cation Transporter 1
      Hong Shen, Wenying Li, W. Griffith Humphreys and Yurong Lai
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 341-342; DOI: https://doi.org/10.1124/jpet.116.238337

  10. Snelder, Nelleke

    1. Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach
      Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach
      Nelleke Snelder, Bart A. Ploeger, Olivier Luttringer, Dean F. Rigel, Randy L. Webb, David Feldman, Fumin Fu, Michael Beil, Liang Jin, Donald R. Stanski and Meindert Danhof
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 356-367; DOI: https://doi.org/10.1124/jpet.116.236208

  11. Stanski, Donald R.

    1. Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach
      Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach
      Nelleke Snelder, Bart A. Ploeger, Olivier Luttringer, Dean F. Rigel, Randy L. Webb, David Feldman, Fumin Fu, Michael Beil, Liang Jin, Donald R. Stanski and Meindert Danhof
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 356-367; DOI: https://doi.org/10.1124/jpet.116.236208

  12. Straiker, Alex

    1. Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists
      Amey Dhopeshwarkar, Natalia Murataeva, Alex Makriyannis, Alex Straiker and Ken Mackie
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 300-311; DOI: https://doi.org/10.1124/jpet.116.236539

  13. Struthers, M.

    1. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder
      J. Di Salvo, H. Nagabukuro, L. A. Wickham, C. Abbadie, J. A. DeMartino, A. Fitzmaurice, L. Gichuru, A. Kulick, M. J. Donnelly, N. Jochnowitz, A. L. Hurley, A. Pereira, A. Sanfiz, G. Veronin, K. Villa, J. Woods, B. Zamlynny, E. Zycband, G.M. Salituro, T. Frenkl, A. E. Weber, S. D. Edmondson and M. Struthers
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 346-355; DOI: https://doi.org/10.1124/jpet.116.237313

T

  1. Tannheimer, Stacey L.

    1. GS-5759, a Bifunctional β2-Adrenoceptor Agonist and Phosphodiesterase 4 Inhibitor for Chronic Obstructive Pulmonary Disease with a Unique Mode of Action: Effects on Gene Expression in Human Airway Epithelial Cells
      Taruna Joshi, Dong Yan, Omar Hamed, Stacey L. Tannheimer, Gary B. Phillips, Clifford D. Wright, Musong Kim, Michael Salmon, Robert Newton and Mark A. Giembycz
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 324-340; DOI: https://doi.org/10.1124/jpet.116.237743

  2. Thrasivoulou, Christopher

    1. Intracellular Calcium Mobilization in Response to Ion Channel Regulators via a Calcium-Induced Calcium Release Mechanism
      Open Access
      Intracellular Calcium Mobilization in Response to Ion Channel Regulators via a Calcium-Induced Calcium Release Mechanism
      Terry Petrou, Hervør L. Olsen, Christopher Thrasivoulou, John R. Masters, Jonathan F. Ashmore and Aamir Ahmed
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 378-387; DOI: https://doi.org/10.1124/jpet.116.236695

  3. Tracy, Kristin

    1. Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease
      Jeffrey Peng, Jill Dalton, Mark Butt, Kristin Tracy, Derek Kennedy, Peter Haroldsen, Rhea Cahayag, Stephen Zoog, Charles A. O’Neill and Laurie S. Tsuruda
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 313-323; DOI: https://doi.org/10.1124/jpet.116.235952

  4. Tsuruda, Laurie S.

    1. Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease
      Jeffrey Peng, Jill Dalton, Mark Butt, Kristin Tracy, Derek Kennedy, Peter Haroldsen, Rhea Cahayag, Stephen Zoog, Charles A. O’Neill and Laurie S. Tsuruda
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 313-323; DOI: https://doi.org/10.1124/jpet.116.235952

V

  1. Vakalopoulos, Costa

    1. The Glutamate Model of Schizophrenia: It’s All About Signal Muscarinic Connections
      Costa Vakalopoulos
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 288; DOI: https://doi.org/10.1124/jpet.116.238766

  2. Veronin, G.

    1. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder
      J. Di Salvo, H. Nagabukuro, L. A. Wickham, C. Abbadie, J. A. DeMartino, A. Fitzmaurice, L. Gichuru, A. Kulick, M. J. Donnelly, N. Jochnowitz, A. L. Hurley, A. Pereira, A. Sanfiz, G. Veronin, K. Villa, J. Woods, B. Zamlynny, E. Zycband, G.M. Salituro, T. Frenkl, A. E. Weber, S. D. Edmondson and M. Struthers
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 346-355; DOI: https://doi.org/10.1124/jpet.116.237313

  3. Villa, K.

    1. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder
      J. Di Salvo, H. Nagabukuro, L. A. Wickham, C. Abbadie, J. A. DeMartino, A. Fitzmaurice, L. Gichuru, A. Kulick, M. J. Donnelly, N. Jochnowitz, A. L. Hurley, A. Pereira, A. Sanfiz, G. Veronin, K. Villa, J. Woods, B. Zamlynny, E. Zycband, G.M. Salituro, T. Frenkl, A. E. Weber, S. D. Edmondson and M. Struthers
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 346-355; DOI: https://doi.org/10.1124/jpet.116.237313

W

  1. Warnken, Mareille

    1. Engineered Context-Sensitive Agonism: Tissue-Selective Drug Signaling through a G Protein-Coupled Receptor
      Wiebke K. Seemann, Daniela Wenzel, Ramona Schrage, Justine Etscheid, Theresa Bödefeld, Anna Bartol, Mareille Warnken, Philipp Sasse, Jessica Klöckner, Ulrike Holzgrabe, Marco DeAmici, Eberhard Schlicker, Kurt Racké, Evi Kostenis, Rainer Meyer, Bernd K. Fleischmann and Klaus Mohr
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 289-299; DOI: https://doi.org/10.1124/jpet.116.237149

  2. Webb, Randy L.

    1. Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach
      Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach
      Nelleke Snelder, Bart A. Ploeger, Olivier Luttringer, Dean F. Rigel, Randy L. Webb, David Feldman, Fumin Fu, Michael Beil, Liang Jin, Donald R. Stanski and Meindert Danhof
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 356-367; DOI: https://doi.org/10.1124/jpet.116.236208

  3. Weber, A. E.

    1. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder
      J. Di Salvo, H. Nagabukuro, L. A. Wickham, C. Abbadie, J. A. DeMartino, A. Fitzmaurice, L. Gichuru, A. Kulick, M. J. Donnelly, N. Jochnowitz, A. L. Hurley, A. Pereira, A. Sanfiz, G. Veronin, K. Villa, J. Woods, B. Zamlynny, E. Zycband, G.M. Salituro, T. Frenkl, A. E. Weber, S. D. Edmondson and M. Struthers
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 346-355; DOI: https://doi.org/10.1124/jpet.116.237313

  4. Wenzel, Daniela

    1. Engineered Context-Sensitive Agonism: Tissue-Selective Drug Signaling through a G Protein-Coupled Receptor
      Wiebke K. Seemann, Daniela Wenzel, Ramona Schrage, Justine Etscheid, Theresa Bödefeld, Anna Bartol, Mareille Warnken, Philipp Sasse, Jessica Klöckner, Ulrike Holzgrabe, Marco DeAmici, Eberhard Schlicker, Kurt Racké, Evi Kostenis, Rainer Meyer, Bernd K. Fleischmann and Klaus Mohr
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 289-299; DOI: https://doi.org/10.1124/jpet.116.237149

  5. Wickham, L. A.

    1. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder
      J. Di Salvo, H. Nagabukuro, L. A. Wickham, C. Abbadie, J. A. DeMartino, A. Fitzmaurice, L. Gichuru, A. Kulick, M. J. Donnelly, N. Jochnowitz, A. L. Hurley, A. Pereira, A. Sanfiz, G. Veronin, K. Villa, J. Woods, B. Zamlynny, E. Zycband, G.M. Salituro, T. Frenkl, A. E. Weber, S. D. Edmondson and M. Struthers
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 346-355; DOI: https://doi.org/10.1124/jpet.116.237313

  6. Woods, J.

    1. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder
      J. Di Salvo, H. Nagabukuro, L. A. Wickham, C. Abbadie, J. A. DeMartino, A. Fitzmaurice, L. Gichuru, A. Kulick, M. J. Donnelly, N. Jochnowitz, A. L. Hurley, A. Pereira, A. Sanfiz, G. Veronin, K. Villa, J. Woods, B. Zamlynny, E. Zycband, G.M. Salituro, T. Frenkl, A. E. Weber, S. D. Edmondson and M. Struthers
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 346-355; DOI: https://doi.org/10.1124/jpet.116.237313

  7. Wright, Clifford D.

    1. GS-5759, a Bifunctional β2-Adrenoceptor Agonist and Phosphodiesterase 4 Inhibitor for Chronic Obstructive Pulmonary Disease with a Unique Mode of Action: Effects on Gene Expression in Human Airway Epithelial Cells
      Taruna Joshi, Dong Yan, Omar Hamed, Stacey L. Tannheimer, Gary B. Phillips, Clifford D. Wright, Musong Kim, Michael Salmon, Robert Newton and Mark A. Giembycz
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 324-340; DOI: https://doi.org/10.1124/jpet.116.237743

Y

  1. Yan, Dong

    1. GS-5759, a Bifunctional β2-Adrenoceptor Agonist and Phosphodiesterase 4 Inhibitor for Chronic Obstructive Pulmonary Disease with a Unique Mode of Action: Effects on Gene Expression in Human Airway Epithelial Cells
      Taruna Joshi, Dong Yan, Omar Hamed, Stacey L. Tannheimer, Gary B. Phillips, Clifford D. Wright, Musong Kim, Michael Salmon, Robert Newton and Mark A. Giembycz
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 324-340; DOI: https://doi.org/10.1124/jpet.116.237743

Z

  1. Zamlynny, B.

    1. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder
      J. Di Salvo, H. Nagabukuro, L. A. Wickham, C. Abbadie, J. A. DeMartino, A. Fitzmaurice, L. Gichuru, A. Kulick, M. J. Donnelly, N. Jochnowitz, A. L. Hurley, A. Pereira, A. Sanfiz, G. Veronin, K. Villa, J. Woods, B. Zamlynny, E. Zycband, G.M. Salituro, T. Frenkl, A. E. Weber, S. D. Edmondson and M. Struthers
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 346-355; DOI: https://doi.org/10.1124/jpet.116.237313

  2. Zhang, Qing

    1. Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension
      Robert J. Aiello, Patricia-Ann Bourassa, Qing Zhang, Jeffrey Dubins, Daniel R. Goldberg, Stéphane De Lombaert, Marc Humbert, Christophe Guignabert, Maria A. Cavasin, Timothy A. McKinsey and Vishwas Paralkar
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 267-279; DOI: https://doi.org/10.1124/jpet.116.237933

  3. Zoog, Stephen

    1. Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease
      Jeffrey Peng, Jill Dalton, Mark Butt, Kristin Tracy, Derek Kennedy, Peter Haroldsen, Rhea Cahayag, Stephen Zoog, Charles A. O’Neill and Laurie S. Tsuruda
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 313-323; DOI: https://doi.org/10.1124/jpet.116.235952

  4. Zycband, E.

    1. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder
      J. Di Salvo, H. Nagabukuro, L. A. Wickham, C. Abbadie, J. A. DeMartino, A. Fitzmaurice, L. Gichuru, A. Kulick, M. J. Donnelly, N. Jochnowitz, A. L. Hurley, A. Pereira, A. Sanfiz, G. Veronin, K. Villa, J. Woods, B. Zamlynny, E. Zycband, G.M. Salituro, T. Frenkl, A. E. Weber, S. D. Edmondson and M. Struthers
      Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 346-355; DOI: https://doi.org/10.1124/jpet.116.237313
Back to top

In this issue